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ABSTRACT: Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breast
carcinoma classifications is based on its molecular aspects and subdivides breast cancer into five major groups
based on the expression of certain genes. In this study, we evaluated which factors are important in determining a
prognosis after 5 years of follow-up for patients with clinical stage IIA breast tumors. We took into consideration
the different phenotypes (luminal A luminal B HER-2 overexpression, basal and triple-negative), various epithelial-
mesenchymal (EMT) molecular markers and adhesion molecules (E-cadherin, P-cadherin, N-cadherin, vimentin,
twist snail and slug) and NOS-2, in addition to clinical and demographic data, tumor characteristics and treatment
types.
METHODS: The study population consisted of 82 patients with breast cancer. We analyzed eight molecular markers
by immunohistochemistry on tissue microarrays containing breast tumor specimens from patients with ten years of
follow-up, and we classified each tumor according to its estrogen receptor, progesterone receptor and HER-2
expression. We then placed the tumor into one of the above categories.
RESULTS: The presence of several clinical and demographic factors, various histopathologies, treatment forms and
several immunohistochemical markers were not associated with a worse prognosis for group IIA patients. The
factors that were associated with a mortality risk were the triple-negative (odds ratio (OR) = 11.8, 95% confident
interval (CI) = 2.0-70.3, P= 0.007) and basal (OR=18.4, 95% CI = 1.8-184.7, P= 0.013) phenotypic patterns.
CONCLUSIONS: The EMT markers and NOS-2 were not mortality risk factors. Basal and triple-negative phenotypic
patterns were related to a higher mortality risk in patients with stage IIA tumors.
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INTRODUCTION
Breast cancer is the most frequent malignant neoplasm
among women worldwide, and in Brazil, and it is one of the
leading causes of cancer-related death.1,2 Despite the
increased incidence in Brazil and other countries, large
international studies show that higher-efficiency screening
programs, better diagnostic image definition and the
appropriate use of adjuvant drug therapies have led to
improved patient survival in the last few decades.3,4 A long-
term survival patient is defined as one who is still living
5 years after first being diagnosed with cancer.5 For breast
cancer, 5- and 10-year survival rates are 88% and 77%,
respectively, both of which are quite good as compared with
the 5-year survival rate of all other types of cancer
combined.5,6 Breast tumors classified as stage IIA are
tumors presenting with local or disseminated disease in
the homolateral axillary lymph nodes. At this stage, around
80% of patients survive disease-free after 5 years;7,8 the data
also show that 20% will die within the same time interval
despite the good prognosis associated with these cases.8
With the evolution of genomic techniques and, conse-
quently, the use of molecular markers, prognostic informa-
tion must be continuously refined. However, these data are
still not sufficient for breast cancer specialists and clinical
oncologists when compared with the standard anatomical-
pathological reports used to determine the best course of
action in some specific cases.
At the beginning of this century, some groups studied the
molecular signature of invasive ductal carcinomas (IDCs)9,10
and showed that the phenotypic diversity in breast tumors
was associated with diversity in gene expression. These gene
expression profiles were called luminal (A and B), HER-2
overexpression, basal and similar to normal breast.
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Importantly, this classification showed prognostic value and
validated well-known clinical behaviors demonstrated in the
literature.
Some molecular markers of epithelial-mesenchymal transi-
tion (EMT) (e.g., vimentin, snail, slug and twist) are correlated
with survival, and their expression may be associated with a
more aggressive phenotype, more mesenchymal differentia-
tion, and thus, decreased survival.11-13 The IHC markers that
have been studied include adhesionmolecules (E-cadherin, N-
cadherin and P-cadherin) and nitric oxide synthase 2 (NOS-2).
On the basis of these observations and with the intention of
improving the immunohistochemical signature of stage IIA
breast tumors, we designed our study to evaluate which
factors affect themortality rate in 10 years of follow-up, taking
into account the different phenotypes (luminal A, luminal B,
HER-2 overexpression, basal and triple-negative), the differ-
ent EMT molecular markers and adhesion molecules (E-
cadherin, P-cadherin, N-cadherin, vimentin, twist, snail and
slug) and NOS-2, in addition to clinical and demographic
data, tumor characteristics and treatment types.
MATERIALS AND METHODS
Study design, patients’ characteristics and tissue
samples
This study design followed the main criteria defined by
REMARK.14 The study population consisted of 82 patients
with IDC who were operated on at A. C. Camargo Hospital
from 1980 to 1999; they were previously identified from
surveys on file in the hospital’s Department of Pathology.
The study protocol was approved by the Research Ethics
Committee at the Center for Treatment and Research,
Cancer Hospital, A. C. Camargo. The patients selected for
this study were diagnosed as having clinical stage IIA breast
cancer (T0N1M0, T1N1M0 and T2N0M0)15 and having a
sufficient amount of representative material from the tumor
for the study. In this study, we analyzed 82 cases of female
patients diagnosed with stage IIA IDC.
We selected patients with a 5-year minimum follow-up
period (60 months). All of the patients were alive, and those
patients with less than 60months of follow-upwere excluded
from the analysis. The maximum follow-up period was
10 years (120 months), and we counted mortality at any time
during the follow-up. The date of the first consultation at the
Department of Mastology, Cancer Hospital, A. C. Camargo,
was considered as the start date for clinical follow-up, and
the date of the last consultation or death was considered as
the end date. We considered those cases in which the patients
did not return for consultation and did not respond to
telephone calls or telegraphs as loss to follow-up.
We reviewed the clinical records, noting the relevant
clinical-pathological information (clinical and demographic
data, anatomopathological staging, therapeutic adjuvant,
follow-up, relapse and survival) in an Excel spreadsheet.
For all of the selected cases, we recovered the original
hematoxylin/eosin (H&E)-stained slides and the corre-
sponding paraffin-embedded tissue blocks, from which we
made new histological sections. Using conventional slides,
we stained the representative areas of the invasive compo-
nent to orient the puncturing and removal of small core
biopsies, which were used to construct a tissue microarray
(TMA). A core was removed from each original tumor block
using a specially designed precision instrument for con-
structing TMAs (Beecher InstrumentsH, Silver Spring,
Maryland), as described previously.16 The diameter of each
block core used for the TMA was 1.0 mm. The histological
sections from the TMA blocks, with an average thickness of
4 mm, were mounted on special electrically charged slides
(Instrumedics Inc.H, Richmond, USA) to facilitate their
orientation after the microtomy and for immunohistochem-
istry (IHC) analysis.
Immunohistochemistry of TMAs
The immunohistochemistry (IHC) study was performed
with antibodies that recognized the different markers used.
For the IHC reactions, we followed the specific standardized
protocols from the manufacturers and previous reports for
each marker. All of the reactions included positive and
negative controls that were stained in parallel with the
slides from the study. Table 1 shows the complete list of the
nine antibodies used with their respective clones, dilutions
and manufacturers.
Evaluation of IHC
Immunostaining was evaluated by light microscopy.
When evaluating the IHC reactions, we took into account
only the percentage of stained cells and classified them
according to a specific expression pattern for each antibody
and the number of positive cells.17 For the nuclear markers,
the cells were considered positive when the percent of
stained nuclei was greater than 1% and negative when this
staining was less than 1%. For cytoplasmic and membra-
nous markers, we considered as positive those cases with
more than 10% stained cells. Examples of positive and
negative cases are shown in Figures 1 through 3.
Table 1 - Antibodies and protocols used in the reactions.
Antibody Clone Dilution Manufacturer
Estrogen receptor Rabbit monoclonal antibody SP1 15400 Neomarkers, CA, USA
Progesterone receptor PgR636 15300 Dako, Carpinteria, CA, USA
HER-2 Rabbit polyclonal RTUa Dako
NOS-2 16 15100 BD Transduction San Jose, CA, USA
Twist 2 3C8 15250 Novus Biologicals, Littleton, USA
Slug Polyclonal 15100 Abcam
Snail E18 15500 Santa Cruz Biotechnology, (Santa Cruz, CA, USA)
Vimentin Vim3B4 15400 Dako, Carpinteria, CA, USA
E-Cadherin 36 15600 BD Transduction San Jose, CA, USA
N-Cadherin 6G-11 1550 Dako, Carpinteria, CA, USA
P-Cadherin 56C1 15100 Neomarkers, CA, USA
aReady to use.
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The IHC slide readings were performed on a shared optic
microscope. ER (estrogen receptor) and PR (progesterone
receptor) status was determined on the basis of IHC staining.
Tumors were considered HER-2-positive only if they were
scored as 3+ by IHC or if they were HER-2 amplified (ratio.
or = 2.0) on the basis of fluorescence in situ hybridization
(FISH). In the absence of positive FISH data, tumors with
indeterminate IHC scores (2+) were considered negative.
Immunophenotypical classification
From the results of the IHC reactions, we identified five
sub-groups based on the immunohistochemical expression
of ER, PR, HER-2 and CK5, 6, as follows: luminal A (ER
positive, PR positive and HER-2 negative), luminal B (ER
positive and/or PR positive and HER-2 positive), HER-2
over-expression (ER negative, PR negative and HER-2
positive), triple-negative (ER negative, PR negative and
HER-2 negative) and basal pattern (ER negative, PR
negative, HER-2 negative and/or CK5 and 6 positive).
Statistical methods
The results were analyzed using SPSS v.13 (SPSS Inc.,
USA, 2004) and GraphPad Prism v.4.02 (GraphPad Software
Inc., USA, 2000). We characterized the sample using
descriptive statistics. We performed association analysis
between categorical variables using the chi-square or
Fisher’s exact test, depending on the values we observed
in the contingency tables. We used logistic regression to
identify independent risk factors associated with mortality.
The final models were adjusted for chemotherapy comple-
tion, hormone therapy and age (as a continuous variable).
The adjustments for age, chemotherapy completion and
hormone therapy were based on a greater potential for
interference with the outcome (death). In all of the models,
the control variables were not significant. For the mortality
analysis, we truncated the follow-up period to 120 months,
and we used a cross-sectional evaluation of the data. A 5%
significance level was used for all of the tests.
RESULTS
When analyzing the stage IIA patients, we observed that
there were no significant associations between mortality and
any of the clinical, demographic or treatment-related
variables (Table 2). When we analyzed the histopathologic
variables, we observed that none of them was significantly
Table 2 - Case distribution according to clinical and demographic variables, histopathologic variables, treatment forms
and mortality within 120 months of follow-upa among women with stage IIA tumors (n= 82).
Mortality within 120 months
No Yes
VARIABLES CATEGORIES n % n % P **
Clinical and Demographica Data
Age Up to 50 years 24 72.7 9 27.3 0.807
.50 years 33 70.2 14 29.8
Skin color White 44 68.8 20 31.3 0.264
Non-white 9 90.0 1 10.0
Number of pregnancies None 10 71.4 4 28.6 1.000
One or more 41 70.7 17 29.3
Hormonal status Pre-menopause 26 72.2 10 27.8 0.744
Post-menopause 31 68.9 14 31.1
Family history No 42 71.2 17 28.8 1.000
Yes 10 71.4 4 28.6
Histopathologya
Tumor size Up to 2.0 cm 14 87.5 2 12.5 0.127
2.1 - 5.0 cm 41 65.1 22 34.9
Scarff-Bloom-Richardson Degrees 1 and 2 50 73.5 18 26.5 0.332
Degree 3 8 57.1 6 42.9
Nuclear grade Degrees 1 and 2 28 87.5 4 12.5 0.008
Degree 3 30 60.0 20 40.0
Mitotic index 0 to 9 37 78.7 10 21.3 0.106
10 or more 9 56.3 7 43.8
Lymph node metastasis No 45 68.2 21 31.8 0.329
Yes 12 86.7 2 14.3
Treatmenta
Neoadjuvant chemotherapy No 49 73.1 18 26.9 0.345
Yes 3 50.0 3 50.0
Neoadjuvant radiotherapy No 50 72.5 19 27.5 0.574
Yes 2 50.0 2 50.0
Adjuvant chemotherapy No 21 70.0 9 30.0 0.846
Yes 31 72.1 12 27.9
Adjuvant radiotherapy No 15 68.2 7 31.8 0.705
Yes 37 72.5 14 27.5
Hormone therapy No 27 79.4 7 20.6 0.149
Yes 45 64.1 14 35.9
aLiving patients with less than 60 months of follow-up were excluded from the analysis.
**Chi-square test or Fisher’s exact test.
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associated with mortality, except for the nuclear grade
variable; the majority of patients who died had grade 3
tumors (P= 0.008) (Table 2). For the biomolecular variables
and mortality, we observed that ER expression was positive
in significantly more patients who did not die than those
that did die (P= 0.021) (Table 3).
When we analyzed the distribution of the cases according
to their phenotypic profile, we observed a larger proportion
of luminal A patients among the patients who did not die
than those that did die (P= 0.006) and a larger proportion of
patients who died in the triple-negative (P= 0.016) and basal
sub-groups (P=0.018) (Table 4).
Using logistic regression, we individually tested the
luminal A, triple-negative and basal phenotype variables
(models) adjusted for age, chemotherapy completion and
hormone therapy, in clinical stage IIA tumors. When
evaluating the mortality risk within 120 months, we
observed that the patients with a phenotypic pattern other
than luminal A had an increased risk of dying (Model A,
OR=6.3, 95% CI = 1.7-22.6, P= 0.005). We also observed that
patients with the triple-negative and basal patterns had an
increased risk of dying, respectively (Model B, OR= 11,8,
95% CI = 2.0-70.3, P= 0.007) and (Model C, OR=18.4, 95%
CI = 1.8-184,7, P= 0.013), independent of the effect of
hormone therapy, adjuvant chemotherapy or age (Table 5).
When analyzing the mortality risk within 120 months
according to luminal B and HER-2 overexpression patterns
in multivariate analysis, (model adjusted for age, hormone
therapy and adjuvant chemotherapy completion), we
observed that these patterns were not associated with a
risk factor of mortality (luminal B, OR=0.9, 95% CI = 0.1-
12.3, P= 0.921) and (HER-2, OR=0.4, 95% CI = 0.1-2.8,
P= 0.342).
DISCUSSION
Breast cancer is one of the most common tumors in
women. According to data from the Instituto Nacional de
Caˆncer INCA (Brazilian National Cancer Institute), there
will be an estimated 49,240 cases of breast cancer in Brazil in
2010.1
Only a few published studies have analyzed which
prognostic factors influence long-term patient survival with
clinical stage IIA breast cancer. This deficit was the main
impetus for conducting our study.
In this study, we analyzed stage IIA breast tumors, taking
into account the variables of age, race, number of
Table 3 - Case distribution according to biomolecular
variables and mortality within 120 months of follow-upa
among women with stage IIA tumors (n= 82).
Mortality within 120 months
No Yes
VARIABLE CATEGORIES n % n % P **
ER Negative 6 42.9 8 57.1 0.021
Positive 52 76.5 16 23.5
PR Negative 19 59.4 13 40.6 0.071
Positive 39 78.0 11 22.0
HER-2 Negative 53 72.6 20 27.4 0.437
Positive 5 55.6 4 44.4
CK 5/6 Negative 49 72.1 19 27.9 0.736
Positive 8 66.7 4 33.3
NOS-2 Negative 18 64.3 10 35.7 0.320
Positive 36 75.0 12 25.0
E-Cadherin Negative 22 62.9 13 37.1 0.146
Positive 32 78.0 9 22.0
N-Cadherin Negative 53 73.6 19 26.4 0.059
Positive 2 33.3 4 66.7
P-Cadherin Negative 30 68.2 14 31.8 0.518
Positive 24 75.0 8 25.0
Vimentin Negative 53 72.6 20 27.4 0.199
Positive 1 33.3 2 66.7
Twist Negative 22 64.7 12 35.3 0.370
Positive 29 74.4 10 25.6
Snail Negative 0 - 0 - NA
Positive 55 71.4 22 28.6
Slug Negative 8 66.7 4 33.3 0.745
Positive 43 70.5 18 29.5
aLiving patients with less than 60 months of follow-up were excluded
from the analysis.
bNot available because of the reduced number of cases in one of the
categories.
**Chi-square test or Fisher’s exact test.
Table 4 - Case distribution according to the phenotypic
biomolecular profile and mortality within 120 months of
follow-upa among women with stage IIA tumors (n= 82).
Mortality within 120 months
No Yes
VARIABLE CATEGORIES n % n % P **
Luminal Ab No 8 44.4 10 55.6 0.006
Yes 50 78.1 14 21.9
Luminal Bb No 56 71.8 22 28.2 0.577
Yes 2 50.0 2 50.0
HER-2 over-
expressionb
No 55 71.4 22 28.6 0.627
Yes 3 60.0 2 40.0
Triple-negativeb No 55 75.3 18 24.7 0.016
Yes 3 33.3 6 66.7
Basalb No 56 75.7 18 24.3 0.018
Yes 2 28.6 5 71.4
aLiving patients with less than 60 months of follow-up were excluded
from the analysis.
bGroup determination:
Luminal A: (ER+ or PR+) and HER-2-.
Luminal B: (ER+ or PR+) and HER-2+.
HER-2 overexpression: ER- and PR- and HER-2+.
Triple-negative: ER- and PR- and HER-2-.
Basal: Triple-negative and (EGFG+ or CK5/6+ or p63n+ or P-cadherin+ or
CK14+).
**Chi-square test or Fisher’s exact test.
Table 5 - Evaluation of the mortality risk within
120 monthsa according to the luminal A, triple-negative
and basal phenotypic patterns using multivariate analysis
(logistic regression). Models were individually adjusted by
age, hormone therapy and adjuvant chemotherapy
(number of deaths considered in the model = 21).
VARIABLE CATEGORY n OR 95% CI P
Luminal A No 16 6.3 1.7-22.6 0.005
Yes 57 1.0 Reference
Triple-negative No 30 1.0 Reference 0.007
Yes 43 11.8 2.0-70.3
Basal No 66 1.0 Reference 0.013
Yes 6 18.4 1.8-184.7
aLiving patients with less than 60 months of follow-up were excluded
from the analysis.
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pregnancies, hormonal status and family history. We did
not find any statistically significant correlation with
mortality risk within the 120-month follow-up period.
According to the literature, one important factor in
determining long-term survival is age.18,19 Younger patients
(30-35 years) have a worse survival rate as compared with
patients aged 70 or older. In our analysis, we did not find
any statistically significant correlation between age and
survival during the 120 months.
Considering the histopathologic variables, we observed
that the nuclear grade variable was the only one associated
with mortality. For variables related to treatment and
mortality within 120 months, none had a statistically
significant association. Several studies have shown an
association between high histological grade and reduced
disease-free survival.18,20-22 The histological grade also has a
significant impact on the selection of patients who will
undergo systemic adjuvant treatment. The histological
grade takes into consideration tubular formation, nuclear
grade and mitotic index.23 However, the individual prog-
nostic value of each one of its components—especially the
nuclear grade—has not received much attention in the
literature.
The patients who were ER-positive had a reduced
mortality rate within the 120-month follow-up period
(P= 0.021). Previous findings have demonstrated that ER
positivity confers a better prognosis for the patients,
independent of sub-group, which allows for the use of
specific anti-hormonal medication.3,6
Luminal A tumors are characterized by their positive ER
expression and/or positive PR expression and negative
HER-2 expression profile.24 According to Zaha et al.,25
tumors in the luminal A sub-group are more often asso-
ciated with ER positivity, a larger percentage of patients in
stages I and II and moderately differentiated tumors.
Fernandes et al.26 observed that the presence of hormone
receptors defines a sub-group with more favorable mor-
phological characteristics.
When analyzing the stage IIA patients in relation to the
mortality risk within 120 months, the multivariate analysis
showed that the patients with a phenotypic pattern other
than luminal A had an increased risk of dying (6.3 times)
within 120 months, independent of the effects of hormone
therapy, chemotherapy and age. We also observed an
increased risk in the triple-negative pattern (11.8 times)
and the basal pattern (18.4 times). Even with statistical
significance, it is important to emphasize that the confidence
interval is very wide because there were few cases with a
positive basal pattern (only six cases in the model).
Although this result should be interpreted with caution,
the basal pattern may nonetheless represent a risk factor for
death.
In general, the literature indicates that patients with a
basal or triple-negative breast tumor pattern have a worse
prognosis.27-29 Haupt et al.30 observed that when a tumor
belonged to the basal sub-group, it was associated with a
worse prognosis in both early and advanced stages in
addition to being more frequently associated with visceral
dissemination. Recently, De Brot et al.31 demonstrated that
patients with basal sub-group tumors had an average
disease-free survival of 28 months and an overall survival
of 36 months, of which only 50% were disease-free. Basal
sub-group tumors also appear to be more common among
young women. In our experience, more than 50% of the
cases in this population have a basal phenotype.32
This association between decreased survival and non-
luminal A tumors can also be analyzed in relation to the
expression of EMTmarkers. The progression of breast cancer
is a result, among others, of a process involving a loss of
epithelial characteristics and the acquisition of mesenchymal
properties, which results in a more aggressive tumor
phenotype.33 Sarrio et al.34 observed a correlation between
EMT and the basal pattern. Makdissi et al.35 observed that in
invasive breast carcinoma, tumor E-cadherin protein expres-
sion may be related to overall breast cancer survival. In our
study, we did not observe a relationship between the
phenotypic profiles and the expression of EMT markers in
stage IIA tumors by IHC. We assume that the expression of
these EMT markers in breast tumors depends on the degree
of transformation of epithelial cells into mesenchymal cells
and that the entire process occurs via specific and complex
regulation, in which each one of these factors can act in a
distinct way during tumor progression.
In conclusion, none of the EMT markers or NOS-2 was
related with mortality risk for stage IIA breast cancer. The
mortality risk was associated with the tumor not belonging
to the luminal A sub-group but instead belonging to the
basal or triple-negative subgroup.
There is still much to learn about the biology of these
tumors, and certainly the variable expression of the different
markers that define basal- and triple-negative-type tumors
should help clarify the distinctions between subpopulations.
Even so, in our study, we observed no correlations between
the studied IHC markers and survival. Thus, robust
population-based studies with appropriate patient popula-
tions are important to define these prognostic factors.
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